S&P 500   5,061.82
DOW   37,735.11
QQQ   431.06
5 Small-Cap Energy Stocks Surged in Price and Volume on Friday
Novo Nordisk Arms Wegovy to Be a Triple Threat
Vital Farms Rides the Pasture-Raised Egg Trend to the Bank
3 Energy Plays for Cash Flow: Buy 1 or Buy Them All
M&T Bank, Goldman Sachs rise; Salesforce, Tesla fall, Monday, 4/15/2024
When Will the Next Bull Market Be?
Global smartphone shipments climb nearly 8% in 1st quarter as Samsung retakes the lead
S&P 500   5,061.82
DOW   37,735.11
QQQ   431.06
5 Small-Cap Energy Stocks Surged in Price and Volume on Friday
Novo Nordisk Arms Wegovy to Be a Triple Threat
Vital Farms Rides the Pasture-Raised Egg Trend to the Bank
3 Energy Plays for Cash Flow: Buy 1 or Buy Them All
M&T Bank, Goldman Sachs rise; Salesforce, Tesla fall, Monday, 4/15/2024
When Will the Next Bull Market Be?
Global smartphone shipments climb nearly 8% in 1st quarter as Samsung retakes the lead
S&P 500   5,061.82
DOW   37,735.11
QQQ   431.06
5 Small-Cap Energy Stocks Surged in Price and Volume on Friday
Novo Nordisk Arms Wegovy to Be a Triple Threat
Vital Farms Rides the Pasture-Raised Egg Trend to the Bank
3 Energy Plays for Cash Flow: Buy 1 or Buy Them All
M&T Bank, Goldman Sachs rise; Salesforce, Tesla fall, Monday, 4/15/2024
When Will the Next Bull Market Be?
Global smartphone shipments climb nearly 8% in 1st quarter as Samsung retakes the lead
S&P 500   5,061.82
DOW   37,735.11
QQQ   431.06
5 Small-Cap Energy Stocks Surged in Price and Volume on Friday
Novo Nordisk Arms Wegovy to Be a Triple Threat
Vital Farms Rides the Pasture-Raised Egg Trend to the Bank
3 Energy Plays for Cash Flow: Buy 1 or Buy Them All
M&T Bank, Goldman Sachs rise; Salesforce, Tesla fall, Monday, 4/15/2024
When Will the Next Bull Market Be?
Global smartphone shipments climb nearly 8% in 1st quarter as Samsung retakes the lead

Compare Stocks

Comparative Price Performance Over Time

Compare Stocks - Price & Volume

CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
Avantor, Inc. stock logo
AVTR
Avantor
$24.71
-1.0%
$24.86
$16.63
$26.16
$16.76B1.375.78 million shs2.40 million shs
Bio-Rad Laboratories, Inc. stock logo
BIO
Bio-Rad Laboratories
$300.41
0.0%
$333.00
$261.59
$489.36
$8.57B0.87199,128 shs167,913 shs
10x Genomics, Inc. stock logo
TXG
10x Genomics
$32.86
-4.9%
$41.22
$32.68
$63.57
$4.12B1.91.21 million shs1.29 million shs
7 Stocks to Buy And Hold Forever Cover

Click the link below and we'll send you MarketBeat's list of seven stocks and why their long-term outlooks are very promising.

Get This Free Report

Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
Avantor, Inc. stock logo
AVTR
Avantor
-1.00%-3.74%-1.48%+13.09%+19.43%
Bio-Rad Laboratories, Inc. stock logo
BIO
Bio-Rad Laboratories
-0.01%-7.93%-9.92%-4.70%-37.32%
10x Genomics, Inc. stock logo
TXG
10x Genomics
-4.89%-9.97%-9.55%-26.17%-39.18%

MarketRank™

CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & Valuation
Avantor, Inc. stock logo
AVTR
Avantor
4.2847 of 5 stars
2.42.00.03.23.42.53.1
Bio-Rad Laboratories, Inc. stock logo
BIO
Bio-Rad Laboratories
4.6856 of 5 stars
3.44.00.04.21.93.31.9
10x Genomics, Inc. stock logo
TXG
10x Genomics
4.2178 of 5 stars
3.42.00.04.82.43.30.6

Analyst Ratings

CompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current Price
Avantor, Inc. stock logo
AVTR
Avantor
2.75
Moderate Buy$26.507.24% Upside
Bio-Rad Laboratories, Inc. stock logo
BIO
Bio-Rad Laboratories
2.80
Moderate Buy$468.0055.79% Upside
10x Genomics, Inc. stock logo
TXG
10x Genomics
2.88
Moderate Buy$60.8885.26% Upside

Current Analyst Ratings

Latest AVTR, BIO, and TXG Analyst Ratings

DateCompanyBrokerageActionRatingPrice TargetDetails
4/10/2024
Avantor, Inc. stock logo
AVTR
Avantor
Barclays
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Boost Price TargetOverweight ➝ Overweight$27.00 ➝ $30.00
4/10/2024
10x Genomics, Inc. stock logo
TXG
10x Genomics
Barclays
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Lower Price TargetOverweight ➝ Overweight$55.00 ➝ $45.00
4/4/2024
Avantor, Inc. stock logo
AVTR
Avantor
Evercore ISI
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Boost Price TargetOutperform ➝ Outperform$26.00 ➝ $28.00
4/3/2024
Bio-Rad Laboratories, Inc. stock logo
BIO
Bio-Rad Laboratories
Citigroup
Subscribe to MarketBeat All Access for the recommendation accuracy rating
DowngradeBuy ➝ Neutral$400.00 ➝ $365.00
2/16/2024
Bio-Rad Laboratories, Inc. stock logo
BIO
Bio-Rad Laboratories
UBS Group
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Boost Price TargetBuy ➝ Buy$395.00 ➝ $420.00
2/16/2024
Bio-Rad Laboratories, Inc. stock logo
BIO
Bio-Rad Laboratories
Royal Bank of Canada
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Lower Price TargetOutperform ➝ Outperform$484.00 ➝ $480.00
2/16/2024
10x Genomics, Inc. stock logo
TXG
10x Genomics
Stifel Nicolaus
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Lower Price TargetBuy ➝ Buy$68.00 ➝ $63.00
2/15/2024
Avantor, Inc. stock logo
AVTR
Avantor
UBS Group
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Boost Price TargetBuy ➝ Buy$25.00 ➝ $29.00
2/15/2024
Avantor, Inc. stock logo
AVTR
Avantor
Citigroup
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Boost Price TargetBuy ➝ Buy$24.00 ➝ $30.00
2/15/2024
Avantor, Inc. stock logo
AVTR
Avantor
JPMorgan Chase & Co.
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Boost Price TargetOverweight ➝ Overweight$26.00 ➝ $29.00
2/15/2024
Avantor, Inc. stock logo
AVTR
Avantor
Robert W. Baird
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Boost Price TargetOutperform ➝ Outperform$25.00 ➝ $26.00
(Data available from 4/16/2021 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Sales & Book Value

CompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/Book
Avantor, Inc. stock logo
AVTR
Avantor
$6.97B2.41$1.66 per share14.87$7.77 per share3.18
Bio-Rad Laboratories, Inc. stock logo
BIO
Bio-Rad Laboratories
$2.67B3.21$12.10 per share24.82$306.51 per share0.98
10x Genomics, Inc. stock logo
TXG
10x Genomics
$618.73M6.33N/AN/A$6.22 per share5.28

Profitability & Earnings

CompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings Date
Avantor, Inc. stock logo
AVTR
Avantor
$321.10M$0.4851.4819.931.574.61%14.11%5.50%4/26/2024 (Confirmed)
Bio-Rad Laboratories, Inc. stock logo
BIO
Bio-Rad Laboratories
-$637.32M-$21.49N/A25.81N/A-23.86%3.90%2.77%5/2/2024 (Estimated)
10x Genomics, Inc. stock logo
TXG
10x Genomics
-$255.10M-$2.17N/AN/AN/A-41.17%-28.82%-22.67%4/30/2024 (Confirmed)

Latest AVTR, BIO, and TXG Earnings

DateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails
4/30/2024N/A
10x Genomics, Inc. stock logo
TXG
10x Genomics
-$0.46N/A+$0.46N/AN/AN/A  
4/26/2024N/A
Avantor, Inc. stock logo
AVTR
Avantor
$0.20N/A-$0.20N/AN/AN/A  
2/15/2024Q4 2023
Bio-Rad Laboratories, Inc. stock logo
BIO
Bio-Rad Laboratories
$2.93$3.10+$0.17-$5.94$685.00 million$681.18 million      
2/15/2024Q4 2023
10x Genomics, Inc. stock logo
TXG
10x Genomics
-$0.36-$0.41-$0.05-$0.41$182.73 million$183.98 million    
2/14/202412/31/2023
Avantor, Inc. stock logo
AVTR
Avantor
$0.22$0.25+$0.03$0.35$1.70 billion$1.72 billion      

Dividends

CompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive Growth
Avantor, Inc. stock logo
AVTR
Avantor
N/AN/AN/AN/AN/A
Bio-Rad Laboratories, Inc. stock logo
BIO
Bio-Rad Laboratories
N/AN/AN/AN/AN/A
10x Genomics, Inc. stock logo
TXG
10x Genomics
N/AN/AN/AN/AN/A

Debt

CompanyDebt-to-Equity RatioCurrent RatioQuick Ratio
Avantor, Inc. stock logo
AVTR
Avantor
1.00
1.61
1.05
Bio-Rad Laboratories, Inc. stock logo
BIO
Bio-Rad Laboratories
0.14
5.83
4.34
10x Genomics, Inc. stock logo
TXG
10x Genomics
N/A
4.69
4.11

Ownership

Institutional Ownership

CompanyInstitutional Ownership
Avantor, Inc. stock logo
AVTR
Avantor
95.08%
Bio-Rad Laboratories, Inc. stock logo
BIO
Bio-Rad Laboratories
65.24%
10x Genomics, Inc. stock logo
TXG
10x Genomics
84.68%

Insider Ownership

CompanyInsider Ownership
Avantor, Inc. stock logo
AVTR
Avantor
1.50%
Bio-Rad Laboratories, Inc. stock logo
BIO
Bio-Rad Laboratories
17.50%
10x Genomics, Inc. stock logo
TXG
10x Genomics
10.65%

Miscellaneous

CompanyEmployeesShares OutstandingFree FloatOptionable
Avantor, Inc. stock logo
AVTR
Avantor
14,500678.28 million669.46 millionOptionable
Bio-Rad Laboratories, Inc. stock logo
BIO
Bio-Rad Laboratories
8,03028.52 million23.53 millionOptionable
10x Genomics, Inc. stock logo
TXG
10x Genomics
1,259119.17 million106.48 millionOptionable

AVTR, BIO, and TXG Headlines

SourceHeadline
Mirae Asset Global Investments Co. Ltd. Sells 79,904 Shares of 10x Genomics, Inc. (NASDAQ:TXG)Mirae Asset Global Investments Co. Ltd. Sells 79,904 Shares of 10x Genomics, Inc. (NASDAQ:TXG)
marketbeat.com - April 16 at 5:04 AM
SVB Wealth LLC Has $80.95 Million Position in 10x Genomics, Inc. (NASDAQ:TXG)SVB Wealth LLC Has $80.95 Million Position in 10x Genomics, Inc. (NASDAQ:TXG)
marketbeat.com - April 15 at 10:06 PM
10x Genomics (NASDAQ:TXG) Hits New 52-Week Low at $33.4710x Genomics (NASDAQ:TXG) Hits New 52-Week Low at $33.47
marketbeat.com - April 15 at 2:48 PM
10x Genomics (NASDAQ:TXG) Shares Gap Down  After Analyst Downgrade10x Genomics (NASDAQ:TXG) Shares Gap Down After Analyst Downgrade
americanbankingnews.com - April 12 at 5:26 AM
Cathie Woods ARK focuses on Teladoc and 10X Genomics stockCathie Wood's ARK focuses on Teladoc and 10X Genomics stock
investing.com - April 11 at 7:21 PM
10x Genomics (NASDAQ:TXG) Price Target Cut to $45.00 by Analysts at Barclays10x Genomics (NASDAQ:TXG) Price Target Cut to $45.00 by Analysts at Barclays
americanbankingnews.com - April 11 at 4:58 AM
10x Genomics to Report First Quarter 2024 Financial Results on April 30, 202410x Genomics to Report First Quarter 2024 Financial Results on April 30, 2024
finance.yahoo.com - April 10 at 7:03 PM
10x Genomics (NASDAQ:TXG) Price Target Cut to $45.0010x Genomics (NASDAQ:TXG) Price Target Cut to $45.00
marketbeat.com - April 10 at 4:19 PM
10x Genomics to Report First Quarter 2024 Financial Results on April 30, 202410x Genomics to Report First Quarter 2024 Financial Results on April 30, 2024
prnewswire.com - April 10 at 4:05 PM
10x Genomics (NASDAQ:TXG) Shares Gap Down to $37.3710x Genomics (NASDAQ:TXG) Shares Gap Down to $37.37
marketbeat.com - April 10 at 11:50 AM
Baillie Gifford & Co. Decreases Stock Holdings in 10x Genomics, Inc. (NASDAQ:TXG)Baillie Gifford & Co. Decreases Stock Holdings in 10x Genomics, Inc. (NASDAQ:TXG)
marketbeat.com - April 9 at 12:12 PM
As 10x Launches Visium HD, Will Single Cell Resolution Draw New Customers?As 10x Launches Visium HD, Will Single Cell Resolution Draw New Customers?
genengnews.com - March 29 at 5:58 PM
ARK Investment Management LLC Acquires 1,047,827 Shares of 10x Genomics, Inc. (NASDAQ:TXG)ARK Investment Management LLC Acquires 1,047,827 Shares of 10x Genomics, Inc. (NASDAQ:TXG)
marketbeat.com - March 28 at 6:39 AM
10x Genomics, Inc. (NASDAQ:TXG) Shares Acquired by Vanguard Group Inc.10x Genomics, Inc. (NASDAQ:TXG) Shares Acquired by Vanguard Group Inc.
marketbeat.com - March 27 at 4:25 AM
10x Genomics Commercially Launches Visium HD Spatial Gene Expression Assay10x Genomics Commercially Launches Visium HD Spatial Gene Expression Assay
finance.yahoo.com - March 26 at 1:11 PM
10x Genomics, Inc: 10x Genomics Expands Xenium Menu with Multi-Modal Cell Segmentation Kit and Immuno-Oncology Gene Panel10x Genomics, Inc: 10x Genomics Expands Xenium Menu with Multi-Modal Cell Segmentation Kit and Immuno-Oncology Gene Panel
finanznachrichten.de - March 23 at 12:22 PM
10x Genomics Expands Xenium Menu with Multi-Modal Cell Segmentation Kit and Immuno-Oncology Gene Panel10x Genomics Expands Xenium Menu with Multi-Modal Cell Segmentation Kit and Immuno-Oncology Gene Panel
finance.yahoo.com - March 21 at 4:46 PM
TXG Nov 2024 40.000 putTXG Nov 2024 40.000 put
ca.finance.yahoo.com - March 16 at 2:48 PM
TXG Aug 2024 60.000 callTXG Aug 2024 60.000 call
ca.finance.yahoo.com - March 16 at 1:47 PM
TXG Dec 2024 40.000 putTXG Dec 2024 40.000 put
ca.finance.yahoo.com - March 16 at 1:47 PM
Insider Selling: 10x Genomics, Inc. (NASDAQ:TXG) CEO Sells 4,660 Shares of StockInsider Selling: 10x Genomics, Inc. (NASDAQ:TXG) CEO Sells 4,660 Shares of Stock
insidertrades.com - March 16 at 9:43 AM
TXG Apr 2024 60.000 callTXG Apr 2024 60.000 call
finance.yahoo.com - March 16 at 12:31 AM
TXG Apr 2024 40.000 putTXG Apr 2024 40.000 put
finance.yahoo.com - March 16 at 12:31 AM
10x Genomics, Inc: 10x Genomics Begins Commercial Shipments of Chromium GEM-X Products10x Genomics, Inc: 10x Genomics Begins Commercial Shipments of Chromium GEM-X Products
finanznachrichten.de - March 14 at 3:19 PM

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

All Headlines

Company Descriptions

Avantor logo

Avantor

NYSE:AVTR
Avantor, Inc. engages in the provision of mission-critical products and services to customers in the biopharma, healthcare, education and government, advanced technologies, and applied materials industries in the Americas, Europe, Asia, the Middle East, and Africa. The company offers materials and consumables, such as purity chemicals and reagents, lab products and supplies, formulated silicone materials, customized excipients, customized single-use assemblies, process chromatography resins and columns, analytical sample prep kits, education and microbiology products, clinical trial kits, peristaltic pumps, and fluid handling tips. It also provides equipment and instrumentation products, including filtration systems, virus inactivation systems, incubators, analytical instruments, evaporators, ultra-low-temperature freezers, biological safety cabinets, and critical environment supplies. In addition, the company offers services and specialty procurements comprising onsite lab and production, clinical, equipment, procurement and sourcing, and biopharmaceutical material scale-up and development services. Further, it provides scientific research support services, such as DNA extraction, bioreactor servicing, clinical and biorepository, and compound management services. The company was founded in 1904 and is headquartered in Radnor, Pennsylvania.
Bio-Rad Laboratories logo

Bio-Rad Laboratories

NYSE:BIO
Bio-Rad Laboratories, Inc. manufactures and distributes life science research and clinical diagnostic products in the United States, Europe, Asia, Canada, and Latin America. It operates through two segments, Life Science and Clinical Diagnostics. The company develops, manufactures, and markets instruments, systems, reagents, and consumables to separate, purify, characterize, and quantitate biological materials such as cells, proteins, and nucleic acids for proteomics, genomics, biopharmaceutical production, cellular biology, and food safety markets. It also designs, manufactures, markets, and supports test systems, informatics systems, test kits, and specialized quality controls for hospitals, diagnostic reference, transfusion, and physician office laboratories. The company offers its products through its direct sales force, as well as through distributors, agents, brokers, and resellers. Bio-Rad Laboratories, Inc. was founded in 1952 and is headquartered in Hercules, California.
10x Genomics logo

10x Genomics

NASDAQ:TXG
10x Genomics, Inc., a life science technology company, develops and sells instruments, consumables, and software for analyzing biological systems in the America, Europe, the Middle East, Africa, China, and the Asia Pacific. The company provides chromium, chromium connect, and chromium controller instruments, microfluidic chips, slides, reagents, and other consumables products. Its single cell solutions runs on its chromium instruments, which include single cell gene expression for measuring gene activity and networks on a cell-by-cell basis; single cell gene expression flex; single cell immune profiling used to study the immune system; single cell Assay for Transposase Accessible Chromati (ATAC) solution to understand the epigenetic state; and single cell multiome ATAC + gene expression which enables simultaneous interrogation of both the RNA and chromatin accessibility, using ATAC in a single cell. The company also provides Visium platform which enables researchers to understand the spatial positions of biological analytes within tissues at high resolution; and Xenium platform for in situ analysis. It serves various academic, government, biopharmaceutical, biotechnology, and other institutions. The company was formerly known as 10X Technologies, Inc. and changed its name to 10x Genomics, Inc. in November 2014. 10x Genomics, Inc. was incorporated in 2012 and is headquartered in Pleasanton, California.